Drug Detail:Xcopri (Cenobamate)
Generic Name: CENOBAMATE 12.5mg; CENOBAMATE 25mg
Dosage Form: tablets
Drug Class: Carbamate anticonvulsants
Drug Detail:Xcopri (Cenobamate)
Generic Name: CENOBAMATE 12.5mg; CENOBAMATE 25mg
Dosage Form: tablets
Drug Class: Carbamate anticonvulsants
XCOPRI may be taken any time with or without food. Swallow tablets whole with liquid. Do not crush or chew.
Monotherapy and Adjunctive Therapy
XCOPRI is administered orally once daily. The recommended dosage and titration, which should not be exceeded because of the potential for serious adverse reactions [see Warnings and Precautions (5.2)], is included in Table 1.
Initial Dosage | |
Week 1 and 2 | 12.5 mg once daily |
Titration Regimen | |
Week 3 and 4 | 25 mg once daily |
Week 5 and 6 | 50 mg once daily |
Week 7 and 8 | 100 mg once daily |
Week 9 and 10 | 150 mg once daily |
Maintenance Dosage | |
Week 11 and thereafter | 200 mg once daily |
Maximum Dosage | |
If needed based on clinical response and tolerability, dose may be increased above 200 mg by increments of 50 mg once daily every two weeks to 400 mg. |
400 mg once daily |
For patients with mild to moderate (5-9 points on Child-Pugh assessment) hepatic impairment, the maximum recommended dosage is 200 mg once daily [see Use in Specific Populations (8.7)]. XCOPRI is not recommended for use in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].